AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27871759
Drug: Basiliximab induction
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Basiliximab induction with low-dose tacrolimus, mycophenolate mofetil, and steroid maintenance therapy (arm A)
Trial: 24383930
Drug: IL-1 receptor
RxNorm normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-1 receptor antagonist (IL-1Ra) 500 mg bolus, then 10 mg/kg/hr infusion for 24 hours
Trial: 22854400
Drug: High-energy density
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-energy density preload (0.97 kcal/g)
Trial: 22854400
Drug: Low-energy density
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-energy density preload (0.57 kcal/g)
Trial: 17097152
Drug: Xylitol 7.5g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylitol 7.5g once daily (QD)
Trial: 16109574
Drug: Esomeprazole-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole-based therapy (20 mg esomeprazole, 1000 mg amoxicillin, 500 mg clarithromycin twice daily for 7 days)
Trial: 16109574
Drug: Omeprazole-based therapy
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole-based therapy (20 mg omeprazole, 1000 mg amoxicillin, 500 mg clarithromycin twice daily for 7 days)
Trial: 16109574
Drug: Esomeprazole-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole-based therapy
Trial: 16109574
Drug: Omeprazole-based therapy
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole-based therapy
Trial: 9469333
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 800 IU daily
Trial: 23756608
Drug: Open-label LDX
RxNorm normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label LDX (20-70 mg/day)
Trial: 19840500
Drug: Immediate post
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate post space preparation using LA Axxess burs
Trial: 19840500
Drug: Delayed post
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed post space preparation using LA Axxess burs
Trial: 19840500
Drug: Immediate post
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate post space preparation using heated pluggers
Trial: 19840500
Drug: Delayed post
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed post space preparation using heated pluggers
Trial: 19840500
Drug: Immediate post
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate post space preparation using solvent delivered with a hand file
Trial: 19840500
Drug: Delayed post
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed post space preparation using solvent delivered with a hand file
Trial: 9305328
Drug: Intravenous levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous levodopa (LD) administered over a wide dose range
Trial: 9305328
Drug: Higher levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Higher levodopa doses
Trial: 9305328
Drug: Smaller, more
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smaller, more frequent levodopa doses
Trial: 9596230
Drug: Nonusers of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonusers of aspirin
Trial: 22694484
Drug: Sumatriptan iontophoretic
RxNorm normalized name: Sumatriptan Iontophoretic Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan iontophoretic transdermal system
Trial: 12720115
Drug: EMD plus
RxNorm normalized name: EMD-1201081
DrugBank: EMD-1201081 (DB06181)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMD plus selective COX-2 inhibitor (rofecoxib 12.5 mg twice daily for 14 days)
Trial: 1514343
Drug: Lignocaine 10
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine 10 mg mixed with propofol
Trial: 27298402
Drug: Salvage treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage treatment for HT
Trial: 19127436
Drug: Indinavir-loaded microparticles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir-loaded microparticles (15% drug load)
Trial: 19127436
Drug: Indinavir-loaded microparticles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir-loaded microparticles (90% drug load)
Trial: 17609916
Drug: Glossy Ganoderma
RxNorm normalized name: Ganoderma lucidum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glossy Ganoderma Decoction (GGD) combined with conventional treatment (penicillin and reduced glutathione)
Trial: 17609916
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (penicillin and reduced glutathione) alone
Trial: 11829202
Drug: Fluconazole (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (150 mg weekly)
Trial: 9625398
Drug: Garlic powder
RxNorm normalized name: Garlic Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic powder (900 mg/d)
Trial: 7836218
Drug: Buffer treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffer treatment (alkali loading) during constant-intensity exercise at 85% of maximal exertion
Trial: 24028076
Drug: No LH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No LH rise prior to ganirelix treatment
Trial: 24028076
Drug: No LH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No LH rise during ganirelix treatment
Trial: 24028076
Drug: Women with
RxNorm normalized name: Arthricare for Women Moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women with LH rise during ganirelix treatment
Trial: 21255534
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg and ASA 325 mg in a single capsule
Trial: 21255534
Drug: Separate monotherapies
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate monotherapies of esomeprazole 40 mg and ASA 325 mg
Trial: 2651244
Drug: Beta-interferon gel
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-interferon gel (100,000 IU/g), self-administered 4 times daily to the affected areas.
Trial: 31825248
Drug: NovoLog® (US-sourced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NovoLog® (US-sourced insulin aspart)
Trial: 31825248
Drug: NovoRapid® (EU-sourced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NovoRapid® (EU-sourced insulin aspart)
Trial: 25539467
Drug: Corticosteroid continuation
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid continuation (CC)
Trial: 21775111
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment (Losartan)
Trial: 19635145
Drug: Powdered supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powdered supplement (30 mg iron as micronized dispersible ferric pyrophosphate, 600 mug folic acid)
Trial: 19635145
Drug: Tablet supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet supplement (27 mg iron from ferrous fumarate, 1000 mug folic acid)
Trial: 15243305
Drug: L-NMMA (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (0.8 mg/min/dL)
Trial: 15243305
Drug: L-NMMA (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (1.6 mg/min/dL)
Trial: 15243305
Drug: L-NMMA (EC50)
RxNorm normalized name: L
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (EC50)
Trial: 15243305
Drug: L-NMMA (Maximal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (Maximal vasoconstrictive response)
Trial: 9271777
Drug: GHRH (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH (50 micrograms hourly between 22.00 h and 1.00 h, 4 x 50 micrograms)
Trial: 8188163
Drug: Interferon-alpha 2a
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha 2a high dose (18 MU/day)
Trial: 8188163
Drug: Interferon-alpha 2a
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha 2a low dose (3 MU/day)
Trial: 2897008
Drug: Ceftriaxone 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 4 g/day
Trial: 29520533
Drug: Acupuncture (AC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (AC) - twice weekly manual acupuncture over six weeks
Trial: 27943570
Drug: Telephone-Delivered Cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-Delivered Cognitive Behavioural Therapy (T-CBT)
Trial: 27943570
Drug: CBT face
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT face to face treatment as usual (TAU-CBT)
Trial: 21672205
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy (CBT) - 5 to 10 sessions based on the Salkovskis/Warwick model.
Trial: 18490527
Drug: Abciximab (glycoprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abciximab (glycoprotein IIb/IIIa inhibitor)
Trial: 18490527
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Stenting with both embolic protection and abciximab)
Trial: 12973486
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg lamivudine daily for 6 months
Trial: 1330079
Drug: Immune Globulin
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune Globulin Intravenous
Trial: 29252011
Drug: Motivational Enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Enhancement Therapy (MET) plus Family Check-Up (FCU)
Trial: 26695436
Drug: NB‐UVB therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NB‐UVB therapy plus intradermal injection of PRP every 2 weeks for 4 months
Trial: 15946597
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Cloril tablet (Test formulation)
Trial: 15946597
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Clozaril tablet (Reference formulation)
Trial: 11942772
Drug: Gemfibrozil (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil (900 mg)
Trial: 14572169
Drug: Micronized fenofibrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized fenofibrate (200 mg)
Trial: 11316966
Drug: Azelastine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine (4 mg)
Trial: 10322842
Drug: Baoyuan Qiangshen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baoyuan Qiangshen (BQ) II tablet
Trial: 3098129
Drug: 4% sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% sodium cromoglycate (SCG) in an oil-in-water cream
Trial: 3098129
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo cream
Trial: 29098469
Drug: Negative control
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative control diet with total fish oil replacement and defatted fish meal containing 0.1-g ARA g‐1 diet
Trial: 28933745
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (160 mg/day for six weeks)
Trial: 24244261
Drug: lenalidomide plus
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: lenalidomide plus cetuximab combination therapy
Trial: 24244261
Drug: lenalidomide 25
RxNorm normalized name: lenalidomide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lenalidomide 25 mg/day monotherapy
Trial: 12656878
Drug: Oral surgeon
RxNorm normalized name: sturgeon, unspecified preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral surgeon
Trial: 12656878
Drug: Oral surgeon
RxNorm normalized name: sturgeon, unspecified preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral surgeon (total time including unscheduled visits)
Trial: 14733634
Drug: High-dose cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cisplatin (HDCP) 100 mg/m2
Trial: 14733634
Drug: Moderate-dose cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate-dose cisplatin (MDCP) 50 mg/m2 combined with ifosfamide (3 g/m2) and mitomycin (6 mg/m2)
Trial: 14733634
Drug: High-dose cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cisplatin (HDCP)
Trial: 14733634
Drug: Moderate-dose cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate-dose cisplatin (MDCP)
Trial: 8960474
Drug: Intraperitoneal cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal cisplatin (100 mg per square meter) plus intravenous cyclophosphamide (600 mg per square meter)
Trial: 8960474
Drug: Intravenous cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cisplatin (100 mg per square meter) plus intravenous cyclophosphamide (600 mg per square meter)
Trial: 11020403
Drug: Trabeculectomy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabeculectomy and Ahmed implant
Trial: 31744345
Drug: CML-enriched maternal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CML-enriched maternal milk formulation (8 mg GA per day)
Trial: 31744345
Drug: Control maternal
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control maternal milk formulation (4 mg GA per day)
Trial: 30992195
Drug: Dapagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (10 mg) and Saxagliptin (2.5 mg)
Trial: 28101379
Drug: Metformin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin treatment for 18 months in daily practice
Trial: 28101379
Drug: Metformin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin treatment for 18 months in RCT
Trial: 20865876
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg x kg(‐1) ketamine, 0.5 mg x kg(‐1) midazolam, 0.02 mg x kg(‐1) atropine
Trial: 20865876
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg x kg(‐1) ketamine, 0.5 mg x kg(‐1) midazolam, 0.02 mg x kg(‐1) atropine
Trial: 8375267
Drug: Bovine NPH
RxNorm normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bovine NPH insulin
Trial: 26383996
Drug: Treatment change
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment change candidates at week 12
Trial: 26383996
Drug: Treatment change
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment change candidates at week 24
Trial: 17456913
Drug: 20% azelaic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% azelaic acid gel
Trial: 15868618
Drug: Human recombinant
RxNorm normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human recombinant relaxin treatment
Trial: 12537345
Drug: GCB (Gluma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GCB (Gluma Comfort Bond) with rescue treatment using Gluma Desensitizer
Trial: 9708388
Drug: Intrasheath injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrasheath injection
Trial: 9708388
Drug: Mixed sheath
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed sheath and subcutaneous injection
Trial: 18683898
Drug: Binge eating
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Binge eating disorder pharmacotherapy trials (specific interventions not detailed in the abstract)
Trial: 18683898
Drug: Exclusionary psychotropic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exclusionary psychotropic medication
Trial: 15627931
Drug: Palpebral hygiene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palpebral hygiene solution used for 3 days
Trial: 15627931
Drug: Palpebral hygiene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palpebral hygiene solution used for 4 days
Trial: 15627931
Drug: Palpebral hygiene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palpebral hygiene solution used for 5 days
Trial: 15627931
Drug: Palpebral hygiene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palpebral hygiene solution used for 6 days
Trial: 1098580
Drug: Matched control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched control (no heparin)
Trial: 28609389
Drug: Conjugated estrogens/MPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens/MPA 1.5 mg
Trial: 26416102
Drug: 1 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 × 10(4) PfSPZ in 50 μL/2 doses
Trial: 26416102
Drug: 1 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 × 10(4) PfSPZ in 10 μL/2 doses
Trial: 26416102
Drug: 5 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 × 10(4) PfSPZ in 10 μL/8 doses
Trial: 26416102
Drug: 5 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 × 10(4) PfSPZ in eight 10 μL injections
Trial: 16045458
Drug: 480 mg
RxNorm normalized name: magaldrate 480 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 480 mg cotrimoxazole (CTX)
Trial: 16045458
Drug: 960 mg
RxNorm normalized name: glycerin 960 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 960 mg cotrimoxazole (CTX)
Trial: 2210587
Drug: Buscopan plus
RxNorm normalized name: Buscopan
DrugBank: Butylscopolamine (DB09300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buscopan plus (hyoscine‐N‐butylbromide 30 mg/day + paracetamol 1500 mg/day)
Trial: 2210587
Drug: Buscopan (hyoscine‐N‐butylbromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buscopan (hyoscine‐N‐butylbromide 30 mg/day)
Trial: 2210587
Drug: Paracetamol (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (1500 mg/day)
Trial: 6786132
Drug: Fresh gas
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh gas flow of 130 ml/kg . min
Trial: 6786132
Drug: Fresh gas
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh gas flow of 100 ml/kg . min
Trial: 6786132
Drug: Fresh gas
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh gas flow of 70 ml/kg . min
Trial: 28759431
Drug: Hyaluronic Acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic Acid Extracellular Matrix and Compression Therapy
Trial: 26721139
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication (75 mg voltaren tablet orally every day for four days)
Trial: 21859991
Drug: BIBF 1120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBF 1120 250 mg, twice per day, continuously for 36 weeks
Trial: 21859991
Drug: BIBF 1120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBF 1120 250 mg
Trial: 17356040
Drug: Intravenous antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antioxidant therapy (n-acetylcysteine, selenium, vitamin C)
Trial: 12930177
Drug: Concurrent resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent resistance and endurance training (C, n = 9)
Trial: 8657760
Drug: Corticosteroid medication
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid medication
Trial: 6439090
Drug: Naloxone hydrochloride
RxNorm normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naloxone hydrochloride (3 mg)
Trial: 26897125
Drug: Hazelnuts (42
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hazelnuts (42 g)
Trial: 26897125
Drug: Chocolate (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chocolate (50 g)
Trial: 26897125
Drug: Potato crisps
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potato crisps (50 g)
Trial: 25652757
Drug: Stanozolol 2
RxNorm normalized name: stanozolol 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stanozolol 2 mg twice daily
Trial: 22699838
Drug: PEG-P (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-P (1.5 g/kg divided twice per day for 2 days)